Search

Nesteroidni antireumatici (NSAR) lijek su izbora u liječenju boli u bolesnika s osteoartritisom (OA). Velik broj različitih NSAR dostupnih na tržištu otežava izbor pojedinoga. Cilj rada: Kritički pregledati tri tipa podataka koji se odnose na NSAR (rezultati istraživanja, kliničko iskustvo i troškovi), radi davanja preporuka kao pomoć pri odlučivanju o terapiji. Materijali i metode: Pretražene su Cochrane, Medline i Embase baze podataka za pregledne članke i kontrolirana randomizirana ispitivanja o kliničkoj djelotvornosti i nuspojavama NSAR. Kliničko iskustvo temelji se na stavovima liječnika-kliničara koautora rada. Podaci o troškovima i prodaji za NSAR odnose se na hrvatsko tržište. Rezultati: Svi NSAR, uključujući i COX-2 selektivne inhibitore, imaju sličnu djelotvornost u kontroli OA boli. Štetni učinak na gornji dio probavnoga trakta najmanji je za diklofenak i ibuprofen, dok za COX-2 selektivne inhibitore, iako vjerojatno manji, nije potpuno utvrđen. Ostale nuspojave rijetko imaju kliničko značenje, a za COX-2 selektivne inhibitore još nisu dovoljno istražene. Dugogodišnje povoljno kliničko iskustvo postoji s diklofenakom i ibuprofenom. Najniži su troškovi liječenja za diklofenak, dok su COX-2 selektivni inhibitori znatno skuplji od neselektivnih NSAR. Zaključak: Diklofenak, a potom ibuprofen ostaju prvi lijek izbora farmakološkog liječenja bolesnika s OA., Non-steroidal anti-inflammatory drugs (NSAIDs) are the treatment of choice for pain control in patients with osteoarthritis (OA). Numerous NSAIDs are available on the market, making a clinical choice difficult. Objective: to review three types of data related to NSAIDs (research results, clinical experience and costs) and thus assist in a clinical decision-making process. Materials and methods: We searched Cochrane, Medline and Embase for systematic reviews and randomized controlled trials about clinical efficacy and side effects of NSAIDs. Clinical experience is based on the opinion of clinicians, i.e. the coauthors of this paper. Costs and sales statistics were obtained for the Croatian drug market. Results: All NSAIDs, including the new selective COX-2 inhibitors, have similar efficacy in controlling the OA pain. Toxicity on upper gastrointestinal tract is the lowest for diclofenac and ibuprofen, whilst for selective COX-2 inhibitors, although probably lower, has not been fully established. Other side effects are rarely clinically relevant and they have not been elucidated for COX-2 inhibitors. There is a long-term favorable clinical experience with the use of diclofenac and ibuprofen. The costs are the lowest for diclofenac, while COX-2 inhibitors are much more expensive than non-selective NSAIDs. Conclusion: Diclofenac, followed by ibuprofen, remains the drug of choice in the pharmacological treatment of OA patients.